USPTO 2015–2025 USPTO PatentsView US Corporation

Emulate, Inc.

USPTO PatentsView assignee record - 77 granted patents across 17 technology areas, active 2017–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C12M (APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERME).

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Explore the portfolio See the ranking

Total patents granted

CPC technology areas

16.0

Avg claims per patent

+392%

5-year filing velocity

The verdict

Emulate holds 77 US patents across 17 technology areas, rank #4,557 of 50,000 tracked assignees.

#4,557
of 50,000 US assignees by volume: Top 22%
by Innovation Score (45.9/100): 16.0
avg claims per patent: +392%
filing velocity, last 5 yrs

Portfolio overview

Emulate, Inc. has been granted 77 US utility patents between 2017 and 2025, placing Emulate, Inc. at rank #4,557 across all assignees tracked by PlainPatent. This portfolio spans 17 distinct Cooperative Patent Classification (CPC) subclasses, averaging 16.0 claims per patent with primary concentration in C12M (APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERME). As a US Corporation, Emulate, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Emulate sits between Cardiovascular Systems, Inc. (77 patents, rank #4,553) and Hangzhou Sanhua Research Institute Co., Ltd. (77 patents, rank #4,561) - the closest US assignees by grant volume. The composite Innovation Score of 45.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 64 grants, compared with 13 in the 2015–2019 window, a +392% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Emulate, Inc.'s 16.0 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 17 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Emulate, Inc. against peers pursuing similar technology classes.

Cardiovascular Sy…

77
Credo Technology…

77
Dong-eui Universi…

77
Dril-quip

77
GAF Energy

77
GE Oil & Gas Pres…

77
GLO AB

77
Hangzhou Sanhua R…

77
Emulate ◀

77

What this shows Emulate holds 77 patents at rank #4,557, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Emulate

By rank, the assignees closest to #4,557 in granted patent volume.

Leaders in C12M (Apparatus FOR Enzymology OR Microbiology)

Other assignees with the most granted patents in Emulate's primary technology class.

Emulate's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

46 Top 22% higher than 78% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2017–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table

Emulate, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2017	1	1.3%
2018	3	3.9%
2019	9	11.7%
2020	8	10.4%
2021	17	22.1%
2022	10	13.0%
2023	12	15.6%
2024	12	15.6%
2025	5	6.5%

Which technologies does Emulate, Inc. patent most?

C12M - APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS 61

B01L - CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE 53

C12N - MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA 44

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 38

A01N - PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF ; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES ; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS 12

C07K - PEPTIDES 9

C12Q - MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES 7

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 3

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 2

B01D - SEPARATION 2

A61L - METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES 1

A61M - DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR 1

G01T - MEASUREMENT OF NUCLEAR OR X-RADIATION 1

B01J - CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS 1

C08J - WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H 1

Top 15 of 17 technology areas

Patent Moat Analysis

Portfolio Volume Light

Tech Breadth Focused

Claim Depth Standard

Velocity Accelerating

Where it ranks

Overall rank by patents

#4,557

Across all tracked assignees

Innovation Score

45.9 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Emulate, Inc. hold?

Emulate, Inc. holds 77 US granted patents filed between 2017 and 2025, spanning 17 technology areas.

What is Emulate, Inc.'s Innovation Score?

Emulate, Inc. has an Innovation Score of 45.9 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Emulate, Inc. focus on?

Emulate, Inc.'s top technology area is C12M (APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS) with 61 patents. The company has filed patents in 17 CPC subclasses total.

Is Emulate, Inc.'s patent filing rate increasing or decreasing?

Emulate, Inc.'s recent filing velocity is +392% compared to the prior five-year period. This indicates accelerating innovation.

What does claim depth mean for Emulate, Inc.'s patents?

Emulate, Inc.'s patents average 16.0 claims each. This falls within the standard range, providing solid legal coverage.

How is the Emulate, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Emulate's 77 grants land it in the top 22% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - Emulate ranks #4,557 of 50,000. Top 50 holders
Most of this portfolio concentrates in C12M - see who else leads that technology area. C12M leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.